Ergomed plc Award of share options (3455T)

TIDMERGO

RNS Number : 3455T

Ergomed plc

03 July 2018

PRESS RELEASE

Ergomed award of share options to Directors and Company Secretary

London, UK - 3 July 2018: Ergomed plc, (LSE:ERGO) ("Ergomed" or the "Company") a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Investment Plan) awards have been made to newly-appointed CFO Stuart Jackson, COO Jan Petracek, and General Counsel and Company Secretary Sanja Juric.

The awards consist of share options over the Company's ordinary shares having a nominal value of 1 pence each (the "Options") with an exercise price of 1 pence per share. Of the total, 50% of the Options will vest after three years and are not subject to performance criteria. The remaining 50% will vest based on total shareholder return over the three year vesting period with a minimum of 15 per cent. per annum. Once vested the options will be exercisable until 1 July 2028.

 
 Director / Executive        Award of Options   Resulting interest   Current shareholding 
                                                    in options          in the Company 
 Stuart Jackson, 
  Chief Financial Officer        400,000             400,000                1,845 
                            -----------------  -------------------  --------------------- 
 Jan Petracek, Chief 
  Operations Officer             400,000             450,000               418,006 
                            -----------------  -------------------  --------------------- 
 Sanja Juric, General 
  Counsel and Company 
  Secretary *                     25,000             175,000                 Nil 
                            -----------------  -------------------  --------------------- 
 

* Sanja Juric also holds 150,000 options over shares owned by Dr Miroslav Reljanovic.

In total 825,000 Options were granted yesterday, representing 1.8 per cent. of the issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                      1) Stuart Jackson 
                                                  2) Jan Petracek 
                                                  3) Sanja Juric 
      -----------------------------------  -------------------------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------------------- 
 a)    Position/status                           1) Chief Financial Officer 
                                                  2) Chief Operations Officer 
                                                  3) General Counsel and Company Secretary 
      -----------------------------------  -------------------------------------------------- 
 b)    Initial notification                      1) Initial Notification 
        /Amendment                                2) Initial Notification 
                                                  3) Initial Notification 
      -----------------------------------  -------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------------- 
 a)    Name                                 Ergomed Plc 
      -----------------------------------  -------------------------------------------------- 
 b)    Legal Entity                         213800BVS8I9VMC1AP84 
        Identifier 
      -----------------------------------  -------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------------------- 
 a)    Description                          Ordinary shares of 1 pence each 
        of the financial 
        instrument, 
        type of instrument                   GB00BN7ZCY67 
 
        Identification 
        code 
      -----------------------------------  -------------------------------------------------- 
 b)    Nature of                            Award of options 
        the transaction 
      -----------------------------------  -------------------------------------------------- 
 c)    Currency                             GBP 
      -----------------------------------  -------------------------------------------------- 
 d)    Price(s) and                                  Price(s)                 Volume(s) 
        volume(s) 
      -----------------------------------  ---------------------------  --------------------- 
        1) Nil                                                                 400,000 
  --------------------------------------------------------------------  --------------------- 
        2) Nil                                                                 450,000 
  --------------------------------------------------------------------  --------------------- 
        3) Nil                                                                 175,000 
  --------------------------------------------------------------------  --------------------- 
 
 e)    Aggregated                           1) 400,000 ordinary shares of 1 pence each, 
        information                          nil consideration 
        - Aggregated                         2) 450,000 ordinary shares of 1 pence each, 
        volume                               nil consideration 
        - Price                              3) 175,000 ordinary shares of 1 pence each, 
        - Aggregated                         nil consideration 
        total 
      -----------------------------------  -------------------------------------------------- 
 f)    Date of the                          03 July 2018 
        transaction 
      -----------------------------------  -------------------------------------------------- 
 g)    Place of the                         Outside a trading venue 
        transaction 
      -----------------------------------  -------------------------------------------------- 
 

ENDS

Enquiries:

 
 Ergomed plc                                      Tel: [phone] 
 Stephen Stamp (Chief Executive Officer) 
 
 Numis Securities Limited                         Tel: [phone] 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
 James Black (Joint Broker) 
 
 N+1 Singer                                       Tel: [phone] 
 Aubrey Powell (Joint Broker) 
 
 Consilium Strategic Communications - for         Tel: [phone] 
  UK enquiries 
 Chris Gardner / Mary-Jane Elliott              [e-mail] 
  Ivar Milligan / Olivia Manser 
 
 MC Services - for Continental European              Tel: [phone] 
  enquiries 
 Anne Hennecke 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCSSIEFEFASEDW

(END) Dow Jones Newswires

July 03, 2018 02:00 ET (06:00 GMT)